Condition: Hepatocellular Carcinoma · Sponsor: Meng Chao Hepatobiliary Hospital of Fujian Medical University
To evaluate the efficacy and safety of camrelizumab combined with apatinib mesylate in the treatment of unresectable hepatocellular carcinoma.
This description comes directly from the study's public registry record.
Yong yi Zeng · 13805083802 · lamp197311@126.com
Always discuss trial participation with your own doctor first.
| Mengchao Hepatobiliary Hospital, Fujian Medical University | Fuzhou, Fujian, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05409482